Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective al...
Q1 2026
May 6, 2026
FY 2025
Mar 12, 2026
Q4 2025
Q3 2025
Nov 10, 2025
Q2 2025
Aug 12, 2025